Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1950 Target Snapshot

Antithrombin-III · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
27Compounds
11Assays
0Approved Drugs
21.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Antithrombin-III shows approved-linked disease relevance led by deep vein thrombosis. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P01008. Start with deep vein thrombosis, then reuse UniProt P01008 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with deep vein thrombosis, then reuse UniProt P01008 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 8 linked drugs
Open source guide
Disease program
deep vein thrombosis

Antithrombin-III shows approved-linked disease relevance led by deep vein thrombosis. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.

Start review with deep vein thrombosis because it currently carries approved-linked support. Linked drugs include BEMIPARIN SODIUM, DALTEPARIN SODIUM, ENOXAPARIN SODIUM, FONDAPARINUX SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 8 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Antithrombin-III as ChEMBL target CHEMBL1950, mapped to UniProt P01008. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Antithrombin-III
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1950
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P01008
Antithrombin-III
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Antithrombin-III is the right protein anchor across sources, using UniProt P01008 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why deep vein thrombosis is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAntithrombin-III
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP01008
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAntithrombin-III
UniProt AccessionP01008
Component TypeProtein
Sequence Length464 aa

Antithrombin-III

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Antithrombin-III, mapped to UniProt P01008. Sequence length is 464 aa.

Mapped IDP01008
Review nameAntithrombin-III
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Antithrombin-III shows approved-linked disease relevance led by deep vein thrombosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
deep vein thrombosis
8 linked drugs · 8 direct · 8 efficacy
Linked drugBEMIPARIN SODIUM
Linked drugDALTEPARIN SODIUM
Linked drugENOXAPARIN SODIUM
Linked drugFONDAPARINUX SODIUM
Approved-linked Approved
venous thromboembolism
7 linked drugs · 7 direct · 7 efficacy
Linked drugDALTEPARIN SODIUM
Linked drugENOXAPARIN SODIUM
Linked drugFONDAPARINUX SODIUM
Linked drugHEPARIN
Approved-linked Approved
Venous thrombosis
7 linked drugs · 7 direct · 7 efficacy
Linked drugDALTEPARIN SODIUM
Linked drugENOXAPARIN SODIUM
Linked drugFONDAPARINUX SODIUM
Linked drugHEPARIN
Approved-linked Approved
Recurrent thrombophlebitis
6 linked drugs · 6 direct · 6 efficacy
Linked drugDALTEPARIN SODIUM
Linked drugDANAPAROID SODIUM
Linked drugENOXAPARIN SODIUM
Linked drugHEPARIN
Approved-linked Approved
Thromboembolism
6 linked drugs · 6 direct · 6 efficacy
Linked drugDALTEPARIN SODIUM
Linked drugENOXAPARIN SODIUM
Linked drugFONDAPARINUX SODIUM
Linked drugHEPARIN
Approved-linked Approved
pulmonary embolism
4 linked drugs · 4 direct · 4 efficacy
Linked drugENOXAPARIN SODIUM
Linked drugFONDAPARINUX SODIUM
Linked drugHEPARIN
Linked drugHEPARIN SODIUM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with deep vein thrombosis because it currently carries approved-linked support. Linked drugs include BEMIPARIN SODIUM, DALTEPARIN SODIUM, ENOXAPARIN SODIUM, FONDAPARINUX SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasedeep vein thrombosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
Assay Mix

Activity Type Distribution

IC5016.0
KD5.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5314374 9.0 Kd 1.0 Clinical
CHEMBL2303815 8.72 Kd 1.9 Preclinical
CHEMBL2303814 8.55 Kd 2.8 Preclinical
CHEMBL1909451 8.15 Kd 7.0 Preclinical
CHEMBL609990 7.24 Kd 58.0 Preclinical
CHEMBL51173 6.24 IC50 570.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
1
6.0
0
6.5
1
7.0
0
7.5
1
8.0
2
8.5
1
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

11
Total Assays
6
Tested Compounds
1
Assay Types
Binding — 11 assays, 6 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 11 6 8.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine